AB Science S.A. (OTCMKTS:ABSCF – Get Free Report) was the target of a significant increase in short interest in May. As of May 29th, there was short interest totaling 140,570 shares, an increase of 805.3% from the May 14th total of 15,528 shares. Based on an average daily trading volume, of 43 shares, the days-to-cover ratio is presently 3,269.1 days.
AB Science Price Performance
OTCMKTS ABSCF opened at $1.12 on Thursday. The stock’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.35. AB Science has a 1-year low of $1.12 and a 1-year high of $1.37.
About AB Science
AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr.
Featured Articles
- Five stocks we like better than AB Science
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
